Natera (NTRA) Reports Q4 Revenue of $660M, Up 39% YoY
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3h ago
0mins
Source: seekingalpha
- Significant Revenue Growth: Natera's Q4 total revenue is expected to be approximately $660 million, reflecting a 39% year-over-year increase, indicating strong market acceptance and demand for its Signatera test in cancer monitoring.
- Impressive Annual Performance: The company anticipates FY 2025 revenues to reach around $2.3 billion, a 35% increase from last year, showcasing Natera's robust growth momentum in the cell-free DNA testing market and solidifying its market leadership.
- Increased Testing Volume: In Q4, Natera processed approximately 923,600 tests, a 17% year-over-year rise, while FY volumes grew 15% to 3,525,500 tests, reflecting ongoing improvements in customer demand and market penetration.
- Strong Cash Flow: Q4 cash inflows stood at roughly $30 million, with FY inflows exceeding $100 million, indicating effective cash flow management that supports future investments and R&D capabilities while expanding operations.
Analyst Views on NTRA
Wall Street analysts forecast NTRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 233.50 USD with a low forecast of 172.00 USD and a high forecast of 280.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 234.310
Low
172.00
Averages
233.50
High
280.00
Current: 234.310
Low
172.00
Averages
233.50
High
280.00
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
